Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Safety evaluation of extracellular vesicles derived from hypoxia primed mesenchymal stem cells of umbilical cord and adipose tissue.

Nguyen QT., Dinh NTH., Hang NT., Van Mao C., Do XH., Le DS.

Animal Study on Systemic / IV, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41102301
PMCID
PMC12533028
DOI
10.1038/s41598-025-20121-7
Citations
4

Abstract (original English)

Extracellular vesicles (EVs) hold great promise as regenerative therapeutics due to their roles in intercellular communication and tissue repair. This study aimed to assess the safety of EVs derived from human mesenchymal stem cells (MSCs) obtained from both umbilical cord (UC-MSC-EVs) and adipose tissue (AD-MSC-EVs) sources, which were manufactured under xeno- and serum-free conditions and primed with 5% O2. EVs from neither source caused vascular or muscular stimulation in New Zealand rabbits. Systemic hypersensitivity tests revealed that neither UC-MSC-EVs nor AD-MSC-EVs triggered significant changes in allergic and immune responses or hematological parameters in the animals, highlighting their biocompatibility and safety when administered systemically. Furthermore, acute toxicity test using Swiss mice showed all mice survived without any signs of acute toxicity after intravenous injection of both types of EVs at very high doses (up to 10,000 µg/kg of body weight). In addition, subchronic toxicity examination in Wistar rats revealed that repeated injections of neither UC-MSC-EVs nor AD-MSC-EVs (50–150 µg/animal) affected hematological indices or the functions of the liver, kidney, or spleen. Collectively, our findings provide strong evidence that both UC-MSC-EVs and AD-MSC-EVs manufactured under xeno- and serum-free conditions and primed with 5% O2 are safe for potential the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsExtracellular VesiclesAdipose TissueHumansUmbilical CordRabbitsRatsMiceMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research